Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of ISIS 301012 (Mipomersen) in Heterozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy

This study has been completed.
Sponsor:
Collaborator:
Ionis Pharmaceuticals, Inc.
Information provided by:
Kastle Therapeutics, LLC
ClinicalTrials.gov Identifier:
NCT00281008
First received: January 20, 2006
Last updated: August 1, 2016
Last verified: August 2016
  Purpose
The aim of this study is to assess the safety and efficacy of varying doses of ISIS 301012 (mipomersen) as add-on therapy in subjects with Heterozygous Familial Hypercholesterolemia

Condition Intervention Phase
Hypercholesterolemia, Familial
Drug: ISIS 301012 or Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2, Double-Blind, Placebo-Controlled, Dose Escalation Study to Assess the Safety, Efficacy, and Pharmacokinetics of ISIS 301012 as Add-on Therapy in Heterozygous Familial Hypercholesterolemia Subjects

Resource links provided by NLM:


Further study details as provided by Kastle Therapeutics, LLC:

Primary Outcome Measures:
  • Percent reduction in LDL-cholesterol from baseline [ Time Frame: Week 7 (Cohorts A-C), Week 15 (Cohort D) ] [ Designated as safety issue: No ]

Enrollment: 44
Study Start Date: February 2006
Study Completion Date: December 2007
Primary Completion Date: July 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cohort A
Loading doses followed by weekly maintenance doses
Drug: ISIS 301012 or Placebo
50 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
Experimental: Cohort B
Loading doses followed by weekly maintenance doses
Drug: ISIS 301012 or Placebo
100 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
Experimental: Cohort C
Loading doses followed by weekly maintenance doses
Drug: ISIS 301012 or Placebo
200 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
Experimental: Cohort D
Loading doses followed by extended weekly maintenance doses
Drug: ISIS 301012 or Placebo
300 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, and 85

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Weight ≥ 50 kg
  • Diagnosis of Heterozygous Familial Hypercholesterolemia.
  • Females must be non-pregnant and non-lactating.
  • On stable lipid lowering therapy for at least 4 weeks.
  • Lipid levels meet the pre-specified criteria.

Exclusion Criteria:

  • Subject had heart problems in the prior 6 months.
  • Subject has elevated ALT, AST, or CPK.
  • History of renal disease, liver disease, or malignancy.
  • Use of oral anticoagulants, unless the dose has been stable for 4 weeks
  • Have any other conditions, which in the opinion of the Investigator would make the subject unsuitable for enrollment, or could interfere with the subject participating in or completing the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00281008

Locations
United States, Illinois
Chicago, Illinois, United States, 60610
United States, Maine
Auburn, Maine, United States, 04210
Scarborough, Maine, United States, 04074
United States, New York
New York City, New York, United States, 10021
United States, North Carolina
Winston-Salem, North Carolina, United States, 27103
United States, Ohio
Cincinnati, Ohio, United States, 45229
United States, Texas
Houston, Texas, United States, 77030
Netherlands
Amsterdam, Netherlands, 1105 AZ
Sponsors and Collaborators
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.
Investigators
Study Director: Medical Monitor Genzyme, a Sanofi Company
  More Information

Responsible Party: Medical Monitor, Genzyme Coporation
ClinicalTrials.gov Identifier: NCT00281008     History of Changes
Other Study ID Numbers: 301012CS9  2005-004797-24 
Study First Received: January 20, 2006
Last Updated: August 1, 2016
Health Authority: United States: Food and Drug Administration
Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)

Keywords provided by Kastle Therapeutics, LLC:
LDL-cholesterol
apoB-100
Heterozygous Familial Hypercholesterolemia

Additional relevant MeSH terms:
Hypercholesterolemia
Hyperlipoproteinemia Type II
Hyperlipidemias
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases
Lipid Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Hyperlipoproteinemias
Mipomersen
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents

ClinicalTrials.gov processed this record on September 26, 2016